GlassScriptPhysician profile
Margeaux King
NPI 1891334454
$4,608.38
in general payments reported to CMS, 2019-2025
29 companies · $807 in 2025
The $807 reported for 2025 was more than what 76% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
See the full distribution for Psychiatric/Mental Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $720 · 2022: $1,037 · 2023: $1,137 · 2024: $907 · 2025: $807.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,851.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,850.71 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $834.09 | 2021-2025 | |
| Axsome Therapeutics, INC. | $555.58 | 2023-2025 | Auvelity, Sunosi |
| Alkermes, INC. | $526.11 | 2021-2025 | Aristada, Lybalvi, Vivitrol |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $335.69 | 2022-2025 | Caplyta |
| Corium, LLC | $291.73 | 2022-2025 | Azstarys |
| Supernus Pharmaceuticals, INC. | $230.21 | 2021-2025 | Qelbree, Qelbree |
| Otsuka America Pharmaceutical, INC. | $181.83 | 2023-2025 | Rexulti, Abilify Maintena, Nuedexta |
| Janssen Pharmaceuticals, INC | $146.76 | 2021-2025 | Spravato |
| Eisai INC. | $137.63 | 2021 | |
| Sunovion Pharmaceuticals INC. | $129.71 | 2021-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $124.19 | 2021-2025 | Trintellix |
| Bausch Health US, LLC | $120.99 | 2023-2025 | Aplenzin, Wellbutrin |
| Neurocrine Biosciences, INC. | $120.22 | 2021-2025 | Ingrezza |
| Teva Pharmaceuticals USA, INC. | $115.57 | 2022-2023 | Austedo, Uzedy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $113.08 | 2024 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tris Pharma INC | $112.26 | 2021-2025 | Dyanavel Xr |
| Ironshore Pharmaceuticals INC. | $94.02 | 2022-2023 | Jornay Pm |
| Lundbeck LLC | $74.98 | 2022-2023 | Rexulti |
| Collegium Pharmaceutical, INC. | $59.43 | 2025 | Jornay Pm |
| Idorsia Pharmaceuticals US INC | $53.41 | 2023-2024 | Quviviq |
| Brainsway USA INC | $45.09 | 2021 | |
| Novo Nordisk INC | $36.72 | 2022-2024 | Wegovy |
| Avanir Pharmaceuticals, INC. | $35.42 | 2021 | |
| Vertical Pharmaceuticals, LLC | $35.00 | 2024-2025 | Relexxii |
| Vanda Pharmaceuticals INC. | $29.80 | 2021 | |
| Allergan, INC. | $19.99 | 2021 | |
| Noven Therapeutics, LLC | $17.96 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $15.86 | 2025 | Cobenfy |
| Tempus Ai, INC | $15.05 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Margeaux King listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.